Boston Private Wealth LLC Acquires New Holdings in IQVIA (IQV)
Boston Private Wealth LLC acquired a new position in IQVIA (NYSE:IQV) in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 83,334 shares of the medical research company’s stock, valued at approximately $8,176,000.
Other large investors have also modified their holdings of the company. BlackRock Inc. bought a new stake in IQVIA in the fourth quarter worth $942,532,000. Icon Advisers Inc. Co. bought a new stake in IQVIA in the fourth quarter worth $852,000. Old Mutual Global Investors UK Ltd. acquired a new position in IQVIA during the 4th quarter worth $675,000. Spark Investment Management LLC acquired a new position in IQVIA during the 4th quarter worth $5,913,000. Finally, Commerce Bank acquired a new position in IQVIA during the 4th quarter worth $20,901,000. Hedge funds and other institutional investors own 92.12% of the company’s stock.
In other news, Director Michael J. Evanisko sold 815 shares of the company’s stock in a transaction dated Wednesday, April 18th. The shares were sold at an average price of $100.00, for a total transaction of $81,500.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Michael J. Evanisko sold 816 shares of the stock in a transaction dated Monday, March 5th. The stock was sold at an average price of $100.00, for a total transaction of $81,600.00. The disclosure for this sale can be found here. Insiders have sold 2,527 shares of company stock valued at $257,834 in the last ninety days. 6.00% of the stock is owned by company insiders.
IQVIA (NYSE:IQV) last announced its quarterly earnings data on Wednesday, May 2nd. The medical research company reported $1.34 EPS for the quarter, beating the Zacks’ consensus estimate of $1.27 by $0.07. The business had revenue of $2.56 billion during the quarter, compared to analyst estimates of $2.42 billion. IQVIA had a net margin of 13.07% and a return on equity of 13.35%. The business’s quarterly revenue was up 34.1% compared to the same quarter last year. equities analysts predict that IQVIA will post 5.06 EPS for the current year.
A number of research analysts have weighed in on the stock. ValuEngine raised shares of IQVIA from a “hold” rating to a “buy” rating in a research report on Wednesday, May 2nd. Argus boosted their target price on shares of IQVIA from $110.00 to $112.00 and gave the stock a “buy” rating in a research report on Monday, April 9th. Zacks Investment Research raised shares of IQVIA from a “sell” rating to a “hold” rating in a research report on Wednesday, April 18th. SunTrust Banks raised shares of IQVIA from a “hold” rating to a “buy” rating in a research report on Wednesday, March 7th. Finally, Piper Jaffray Companies reissued a “hold” rating and set a $103.00 target price on shares of IQVIA in a research report on Thursday, February 15th. Seven investment analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $110.47.
IQVIA Holdings Inc provides integrated information and technology-enabled healthcare services in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Commercial Solutions, Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offers a range of cloud-based applications and related implementation, real-world insights, and reference information services; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services.
Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.